Cargando…

Characterisation of urinary monocyte chemoattractant protein 1: Potential biomarker for patients with overactive bladder

Objective: To investigate urinary monocyte chemoattractant protein 1 (MCP-1) as a potential marker for idiopathic overactive bladder (OAB). This is a quantitative measurement of urinary MCP-1 to establish baseline normal values that could help in future index studies. Normalised urinary MCP-1 levels...

Descripción completa

Detalles Bibliográficos
Autores principales: Farhan, Bilal, Chang, Huiyi, Ahmed, Ahmed, Zaldivair, Frank, Ghoniem, Gamal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6583746/
https://www.ncbi.nlm.nih.gov/pubmed/31258944
http://dx.doi.org/10.1080/2090598X.2019.1589932
_version_ 1783428443163066368
author Farhan, Bilal
Chang, Huiyi
Ahmed, Ahmed
Zaldivair, Frank
Ghoniem, Gamal
author_facet Farhan, Bilal
Chang, Huiyi
Ahmed, Ahmed
Zaldivair, Frank
Ghoniem, Gamal
author_sort Farhan, Bilal
collection PubMed
description Objective: To investigate urinary monocyte chemoattractant protein 1 (MCP-1) as a potential marker for idiopathic overactive bladder (OAB). This is a quantitative measurement of urinary MCP-1 to establish baseline normal values that could help in future index studies. Normalised urinary MCP-1 levels are measured in female patients with OAB and aged-matched controls. Severity of OAB symptoms is correlated to normalised urinary MCP-1 levels. Patients and methods: Urinary MCP-1 levels were measured in 29 female patients with OAB and 10 normal female controls. The patients with OAB were either newly diagnosed or off any OAB oral therapy for at least 2 weeks. OAB symptoms were assessed using validated OAB questionnaires. Urinary MCP-1 levels were measured using enzyme-linked immunosorbent assay and normalised by urinary creatinine (Cr) levels. Results: The baseline urinary MCP-1 levels in female patients with OAB were significantly higher than those of the controls, at a mean of 210.25 vs 48.02 pg/mg Cr (P < 0.001). Patients who had severe OAB bother symptoms had higher levels of urinary MCP-1 (r = 0.03), also patients with OAB-wet had higher levels of urinary MCP-1, at a mean (SEM) of 209.25 (30.5) vs OAB-dry 185.25 (10) pg/mg Cr (P < 0.001). Conclusion: Urinary MCP-1 levels were higher in female patients with idiopathic OAB. The close association of urinary MCP-1 and OAB bother severity symptoms and OAB-wet suggest that inflammation plays a major role in the pathophysiological mechanisms underlying the sensitisation of bladder afferent nerves. Establishing urinary MCP-1 levels in patients with OAB hopefully will help future studies to confirm the correlation as a baseline and changes with treatments. Abbreviations: BMI: body mass index; Cr: creatinine; MCP-1: monocyte chemoattractant protein 1; OAB: overactive bladder; OAB-q: Overactive Bladder Questionnaire; PPBC: Patient Perception of Bladder Condition; UI: urinary incontinence
format Online
Article
Text
id pubmed-6583746
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-65837462019-06-28 Characterisation of urinary monocyte chemoattractant protein 1: Potential biomarker for patients with overactive bladder Farhan, Bilal Chang, Huiyi Ahmed, Ahmed Zaldivair, Frank Ghoniem, Gamal Arab J Urol Pelvic Floor Disorders and Overactive Bladder Objective: To investigate urinary monocyte chemoattractant protein 1 (MCP-1) as a potential marker for idiopathic overactive bladder (OAB). This is a quantitative measurement of urinary MCP-1 to establish baseline normal values that could help in future index studies. Normalised urinary MCP-1 levels are measured in female patients with OAB and aged-matched controls. Severity of OAB symptoms is correlated to normalised urinary MCP-1 levels. Patients and methods: Urinary MCP-1 levels were measured in 29 female patients with OAB and 10 normal female controls. The patients with OAB were either newly diagnosed or off any OAB oral therapy for at least 2 weeks. OAB symptoms were assessed using validated OAB questionnaires. Urinary MCP-1 levels were measured using enzyme-linked immunosorbent assay and normalised by urinary creatinine (Cr) levels. Results: The baseline urinary MCP-1 levels in female patients with OAB were significantly higher than those of the controls, at a mean of 210.25 vs 48.02 pg/mg Cr (P < 0.001). Patients who had severe OAB bother symptoms had higher levels of urinary MCP-1 (r = 0.03), also patients with OAB-wet had higher levels of urinary MCP-1, at a mean (SEM) of 209.25 (30.5) vs OAB-dry 185.25 (10) pg/mg Cr (P < 0.001). Conclusion: Urinary MCP-1 levels were higher in female patients with idiopathic OAB. The close association of urinary MCP-1 and OAB bother severity symptoms and OAB-wet suggest that inflammation plays a major role in the pathophysiological mechanisms underlying the sensitisation of bladder afferent nerves. Establishing urinary MCP-1 levels in patients with OAB hopefully will help future studies to confirm the correlation as a baseline and changes with treatments. Abbreviations: BMI: body mass index; Cr: creatinine; MCP-1: monocyte chemoattractant protein 1; OAB: overactive bladder; OAB-q: Overactive Bladder Questionnaire; PPBC: Patient Perception of Bladder Condition; UI: urinary incontinence Taylor & Francis 2019-04-04 /pmc/articles/PMC6583746/ /pubmed/31258944 http://dx.doi.org/10.1080/2090598X.2019.1589932 Text en © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Pelvic Floor Disorders and Overactive Bladder
Farhan, Bilal
Chang, Huiyi
Ahmed, Ahmed
Zaldivair, Frank
Ghoniem, Gamal
Characterisation of urinary monocyte chemoattractant protein 1: Potential biomarker for patients with overactive bladder
title Characterisation of urinary monocyte chemoattractant protein 1: Potential biomarker for patients with overactive bladder
title_full Characterisation of urinary monocyte chemoattractant protein 1: Potential biomarker for patients with overactive bladder
title_fullStr Characterisation of urinary monocyte chemoattractant protein 1: Potential biomarker for patients with overactive bladder
title_full_unstemmed Characterisation of urinary monocyte chemoattractant protein 1: Potential biomarker for patients with overactive bladder
title_short Characterisation of urinary monocyte chemoattractant protein 1: Potential biomarker for patients with overactive bladder
title_sort characterisation of urinary monocyte chemoattractant protein 1: potential biomarker for patients with overactive bladder
topic Pelvic Floor Disorders and Overactive Bladder
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6583746/
https://www.ncbi.nlm.nih.gov/pubmed/31258944
http://dx.doi.org/10.1080/2090598X.2019.1589932
work_keys_str_mv AT farhanbilal characterisationofurinarymonocytechemoattractantprotein1potentialbiomarkerforpatientswithoveractivebladder
AT changhuiyi characterisationofurinarymonocytechemoattractantprotein1potentialbiomarkerforpatientswithoveractivebladder
AT ahmedahmed characterisationofurinarymonocytechemoattractantprotein1potentialbiomarkerforpatientswithoveractivebladder
AT zaldivairfrank characterisationofurinarymonocytechemoattractantprotein1potentialbiomarkerforpatientswithoveractivebladder
AT ghoniemgamal characterisationofurinarymonocytechemoattractantprotein1potentialbiomarkerforpatientswithoveractivebladder